Henry Schein (NASDAQ:HSIC - Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 4.740-4.820 for the period, compared to the consensus estimate of 4.750. The company issued revenue guidance of $12.8 billion-$13.0 billion, compared to the consensus revenue estimate of $12.9 billion.
Several research analysts recently commented on HSIC shares. UBS Group dropped their price target on Henry Schein from $75.00 to $72.00 and set a "neutral" rating for the company in a research report on Wednesday, August 7th. Robert W. Baird cut their target price on Henry Schein from $92.00 to $82.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 7th. Barrington Research restated an "outperform" rating and set a $82.00 price target on shares of Henry Schein in a report on Friday, September 20th. Baird R W upgraded shares of Henry Schein from a "hold" rating to a "strong-buy" rating in a research report on Monday, July 22nd. Finally, StockNews.com downgraded shares of Henry Schein from a "hold" rating to a "sell" rating in a research note on Wednesday, October 30th. Two analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $77.50.
Read Our Latest Report on HSIC
Henry Schein stock opened at $72.33 on Tuesday. Henry Schein has a fifty-two week low of $62.05 and a fifty-two week high of $82.63. The company has a market capitalization of $9.16 billion, a PE ratio of 26.79, a P/E/G ratio of 2.02 and a beta of 0.87. The company has a 50 day moving average price of $70.66 and a 200-day moving average price of $69.79. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.90 and a current ratio of 1.55.
Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.01. The firm had revenue of $3.10 billion during the quarter, compared to analysts' expectations of $3.27 billion. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The company's revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.31 EPS. As a group, equities analysts forecast that Henry Schein will post 4.74 earnings per share for the current year.
In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of Henry Schein stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total value of $1,457,725.50. Following the transaction, the senior vice president now owns 71,833 shares in the company, valued at $4,978,026.90. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.14% of the company's stock.
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Henry Schein, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.
While Henry Schein currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.